555 related articles for article (PubMed ID: 9258460)
61. Preparation, characterization, and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting.
Jia F; Shelton TD; Lewis MR
Cancer Biother Radiopharm; 2007 Oct; 22(5):654-64. PubMed ID: 17979568
[TBL] [Abstract][Full Text] [Related]
62. Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft.
Gu W; Yudistiro R; Hanaoka H; Katsumata N; Tsushima Y
Ann Nucl Med; 2021 Apr; 35(4):514-522. PubMed ID: 33582981
[TBL] [Abstract][Full Text] [Related]
63. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
Pedley RB; Boden JA; Boden R; Boxer GM; Flynn AA; Keep PA; Begent RH
Cancer Res; 1996 Jul; 56(14):3293-300. PubMed ID: 8764124
[TBL] [Abstract][Full Text] [Related]
64. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer.
Bos ES; Kuijpers WH; Meesters-Winters M; Pham DT; de Haan AS; van Doornmalen AM; Kaspersen FM; van Boeckel CA; Gougeon-Bertrand F
Cancer Res; 1994 Jul; 54(13):3479-86. PubMed ID: 8012970
[TBL] [Abstract][Full Text] [Related]
65. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
66. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
67. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
Stastny JJ; Das Gupta TK
Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
[TBL] [Abstract][Full Text] [Related]
68. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
[TBL] [Abstract][Full Text] [Related]
69. Carcinoembryonic antigen and alpha-fetoprotein expression and monoclonal antibody targeting in a human hepatoma/nude mouse model.
Wang ZF; Stein R; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):869s-872s. PubMed ID: 1688735
[TBL] [Abstract][Full Text] [Related]
70. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).
Siler K; Eggensperger D; Hand PH; Milenic DE; Miller LS; Houchens DP; Hinkle G; Schlom J
Biotechnol Ther; 1993; 4(3-4):163-81. PubMed ID: 8292968
[TBL] [Abstract][Full Text] [Related]
71. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
72. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
73. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
74. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
75. Interferon-alpha-2b immunoconjugate for improving immunoscintigraphy and immunotherapy.
Pallela VR; Rao SP; Thakur ML
J Nucl Med; 2000 Jun; 41(6):1108-13. PubMed ID: 10855643
[TBL] [Abstract][Full Text] [Related]
76. Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application.
Werlen RC; Lankinen M; Offord RE; Schubiger PA; Smith A; Rose K
Cancer Res; 1996 Feb; 56(4):809-15. PubMed ID: 8631018
[TBL] [Abstract][Full Text] [Related]
77. Improved antibody targeting with interferon-alpha-2b conjugate.
Thakur ML; Li J; Donegan M; Pallela VR; Kolan H; Duggaraju R; Maish D; Srivastava S
J Immunother; 1997 May; 20(3):194-201. PubMed ID: 9181457
[TBL] [Abstract][Full Text] [Related]
78. Experimental approaches to increase radiolabeled antibody localization in tumors.
Buchsbaum DJ
Cancer Res; 1995 Dec; 55(23 Suppl):5729s-5732s. PubMed ID: 7493336
[TBL] [Abstract][Full Text] [Related]
79. Use of second antibody in radioimmunotherapy.
Begent RH; Bagshawe KD; Pedley RB; Searle F; Ledermann JA; Green AJ; Keep PA; Chester KA; Glaser MG; Dale RG
NCI Monogr; 1987; (3):59-61. PubMed ID: 3493442
[TBL] [Abstract][Full Text] [Related]
80. Stability, characterization, and kinetics of 111In-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models.
Halpern SE; Hagan PL; Garver PR; Koziol JA; Chen AW; Frincke JM; Bartholomew RM; David GS; Adams TH
Cancer Res; 1983 Nov; 43(11):5347-55. PubMed ID: 6616469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
